India to United Kingdom: Amoxicillin Export Trade Route

To import licensed human medicines into the UK, entities must obtain the following authorizations:

• Wholesale Distribution Authorisation (WDA(H)): Permits the wholesale distribution of medicinal products.

• Manufacturer's Licence: Required for manufacturing or assembling medicinal products.

• Marketing Authorisation (MA): Also known as a product licence, this is mandatory before a human medicine can be sold in the UK.

The application process for a Marketing Authorisation involves submitting a dossier in the Common Technical Document (CTD) or electronic CTD (eCTD) format. The MHRA conducts inspections of manufacturing sites to ensure compliance with Good Manufacturing Practice (GMP) standards. A Qualified Person (QP) named in the manufacturer's licence must certify that each batch has been manufactured and tested according to the MA and GMP requirements. (gov.uk)

Indian manufacturers exporting Amoxicillin formulations to the UK must comply with GMP standards equivalent to those in the UK. The MHRA maintains a list of GMP-compliant manufacturers, including those in India. For instance, as of February 5, 2024, Baxter Pharmaceuticals India Private Limited in Ahmedabad, India, holds a valid GMP certificate issued by the MHRA. (cms.mhra.gov.uk)

The MHRA conducts inspections of overseas manufacturing facilities to ensure compliance with GMP standards. These inspections are critical for maintaining the validity of GMP certificates and the ability to export to the UK market.

In October 2024, the MHRA published new guidance for pharmaceutical manufacturers and wholesalers to implement the arrangements of the Windsor Framework for human medicines, effective from January 1, 2025. This guidance covers labeling, packaging, and importing requirements, including the use of 'UK Only' labels and the disapplication of the EU Falsified Medicines Directive (FMD). Specific instructions are provided for Qualified Persons (QPs) and Responsible Persons for Import (RPis).

Additionally, in January 2026, WuXi Biologics announced that two of its manufacturing facilities in Wuxi received GMP certifications from the MHRA for commercial manufacturing of an ophthalmic biologic. This underscores the MHRA's ongoing commitment to ensuring GMP compliance among international manufacturers supplying the UK market.

These developments highlight the MHRA's continuous efforts to uphold stringent regulatory standards for pharmaceutical imports, ensuring the safety and efficacy of medicines available in the UK.

In 2024, the United Kingdom's antibiotics market was valued at approximately $2,687.1 million, with projections indicating growth to $3,822.5 million by 2033, reflecting a compound annual growth rate (CAGR) of 3.9% from 2025 to 2033. Amoxicillin, a widely prescribed antibiotic, contributes significantly to this market. The increasing prevalence of bacterial infections, an aging population, and substantial healthcare spending are primary drivers of demand. The UK's universal health coverage ensures broad access to antibiotics, further bolstering consumption. While the UK maintains domestic pharmaceutical manufacturing capabilities, it also relies on imports to meet demand. In 2024, India exported finished pharmaceutical formulations containing amoxicillin to the UK valued at $16.0 million, accounting for 2.6% of India's total amoxicillin formulation exports.

The United Kingdom imposes a Most-Favored-Nation (MFN) import duty rate of 0.00% on pharmaceutical products classified under HS code 30041030, which includes finished formulations containing amoxicillin. This duty-free status facilitates the importation of these essential medicines. Additionally, the UK does not levy anti-dumping duties on these imports. As of March 2026, there is no Free Trade Agreement (FTA) between India and the United Kingdom specifically affecting pharmaceutical tariffs.

India is a key supplier of finished pharmaceutical formulations containing amoxicillin to the United Kingdom, with exports valued at $16.0 million in 2024. Other major suppliers include European Union countries and China. India's competitive pricing, coupled with its robust pharmaceutical manufacturing infrastructure, positions it favorably in the UK market. The top Indian exporters to the UK in 2024 were Medreich Limited ($6.9 million), Micro Labs Limited ($2.9 million), and Milan Laboratories (India) Private Limited ($2.6 million). The UK's top buyers of these formulations from India included Medreich PLC ($6.9 million) and Brown and Burk UK Limited ($2.9 million). This trade dynamic underscores India's significant role in supplying cost-effective amoxicillin formulations to the UK market.

India has solidified its position as a global leader in the production of generic pharmaceutical formulations, including those containing Amoxicillin. As of 2025, the country accounts for approximately 31.9% of the United States' imports of finished dosage forms (FDFs), underscoring its significant role in the global pharmaceutical supply chain.

The nation's manufacturing infrastructure is robust, with numerous facilities dedicated to producing finished dosage forms such as tablets, capsules, and syrups. For instance, FDC India's Baddi facility specializes in Cephalosporins and their combinations, boasting capacities of 330 million tablets and 750,000 bottles of oral liquids per month.

India's cost advantages are notable, stemming from economies of scale, a skilled workforce, and a favorable regulatory environment. These factors enable the production of high-quality Amoxicillin formulations at competitive prices. The country also hosts a substantial number of WHO-GMP and US FDA-approved facilities, ensuring compliance with stringent international quality standards. For example, Indoco Remedies' sterile drug product manufacturing facility in Goa received a Certificate of EU GMP Compliance in 2025.

When comparing Amoxicillin formulation exports, India offers a compelling balance of cost and quality. In 2024, China led global exports of medicaments containing antibiotics, not for retail, with a trade value of $475.6 million and a volume of 66,507,100 kg. The European Union followed with exports valued at $169.9 million and a volume of 1,008,060 kg.

While China provides cost-effective options, concerns about quality and regulatory compliance persist. The European Union is renowned for high-quality, branded generics but often at higher price points. India strikes a balance, offering competitively priced Amoxicillin formulations that meet international quality standards. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) recognizes and approves Indian manufacturing facilities, reflecting confidence in their compliance and quality.

India's Amoxicillin formulation supply chain to the United Kingdom is characterized by reliability and substantial manufacturing capacity. Facilities like FDC India's Baddi plant, with its significant production capabilities, exemplify this strength. The country's packaging and cold chain logistics are well-developed, ensuring the integrity of pharmaceutical products during transit.

Indian manufacturers have a strong track record of regulatory compliance. For instance, Indoco Remedies received an Establishment Inspection Report (EIR) from the US FDA for its API manufacturing facility at Patalganga in 2025. While no significant supply disruptions have been reported recently, ongoing investments in capacity expansion and technological upgrades further bolster supply reliability.

For UK buyers sourcing Amoxicillin formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Be aware that MOQs can vary; establishing clear communication with suppliers will help align expectations and ensure consistent supply.

• Payment Terms: Standard terms often include letters of credit or advance payments. Negotiating favorable terms can enhance financial planning and cash flow management.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and quality assessments, to ensure compliance with UK regulatory standards.

• Regulatory Compliance: Verify that selected suppliers have the necessary approvals from the MHRA and other relevant authorities to facilitate smooth importation and distribution within the UK.

Before engaging with an Indian manufacturer for Amoxicillin formulations, United Kingdom buyers should adhere to the following checklist:

When sourcing Amoxicillin formulations from Indian suppliers, United Kingdom buyers should request the following documents:

When evaluating Indian Amoxicillin suppliers, be vigilant for the following red flags:

To ensure the quality and compliance of Indian Amoxicillin manufacturers, United Kingdom buyers should implement the following audit and monitoring procedures:

By adhering to these guidelines, United Kingdom buyers can establish and maintain robust supplier relationships with Indian manufacturers, ensuring the consistent quality and compliance of Amoxicillin formulations imported into the UK.